Accelsius recently secured strategic investment from Johnson Controls and introduced its NeuCool® MR250 system; pipeline of opportunities now exceeds $1 billion AeroFlexx delivered 5th consecutive quarter of revenue generation with growing customer pipeline in U.S. and Europe Refinity on track to demonstrate pilot scale and finalize initial site selection for first plant by year-end ORLANDO, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industrial growth conglomerate, today announced financial results for the quarter ended September 30, 2025. “Innventure’s momentum continued in the third quarter, driven by meaningful execution across our operating companies. Accelsius, AeroFlexx, and Refinity each advanced key commercial and technical milestones, reinforcing our belief that Innventure...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively express genetic medicines at the tumor site Established new Scientific Advisory Board to support development of CLD-401 and advance RedTail platform for the systemic delivery of targeted genetic medicine  Continued expansion of RedTail platform capabilities with multiple additional payloads and programable membrane targeting, further advancing virotherapy in cancer and beyond oncology Raised $6.9 million gross proceeds through an underwritten public offering with new and existing investors that further strengthens the company’s balance sheet and extends its runwaySAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Calidi...

Sales Revenue Up 135% over Q3 2024 FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial HighlightsTotal revenue reported for Q3 2025 was $226,000, an increase of 135% compared with $96,000 in Q3 2024. Total revenue was $581,000 for the nine months ended September 30, 2025, compared with $271,000 for the nine months ended September 30, 2024, an increase of 114%. GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $4,120,000 in Q3 2024. GAAP net loss for the nine months ended September 30, 2025 and 2024 was $11,405,000,...

Transformational Quarter Strengthens Balance Sheet, Launches LINK-Anchored Digital Asset Treasury, and Positions Caliber on Path to Adjusted EBITDA Profitability SCOTTSDALE, Ariz., Nov. 13, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today reported results for the third quarter ended on September 30, 2025. Third Quarter 2025 HighlightsRaised more than $30.0 million through common and preferred equity, strengthening Caliber’s balance sheet and liquidity. Launched Caliber’s Digital Asset Treasury (“DAT”) anchored in Chainlink (LINK) tokens, expanding the Company’s business into digital asset management alongside its core Private Equity Real Estate (PERE) platform.Third Quarter 2025 Platform Financial Results (compared to Third Quarter 2024)Platform revenue...

AUSTIN, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the first quarter of fiscal year 2026, which ended September 30, 2025. Financial Highlights & Recent Developments   Revenue increased to $297 thousand or 35% in the first quarter of fiscal year 2026 as compared to the fourth quarter of fiscal year 2025 as Astrotech’s subsidiary, 1st Detect, had more grant revenue and sold more consumables compared to prior quarter. As of September 30, 2025, the Company has deployed the TRACER 1000 in approximately 34 locations in 16 countries across the United States, Europe and Asia. On August 18, 2025, the Company announced that the Board of Directors of the Company had appointed Mr. Nihanth Badugu as Chief Operating Officer of the Company...

Record Q4 and Full Year Revenue & PLOStrong Growth in Diluted EPS & Adjusted EBITDA AUSTIN, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — EZCORP, Inc. (NASDAQ: EZPW), a leading provider of pawn transactions in the United States and Latin America, today announced results for its fourth quarter and full year ended September 30, 2025. Unless otherwise noted, all amounts in this release are in conformity with U.S. generally accepted accounting principles (“GAAP”) and comparisons shown are to the same period in the prior year. FOURTH QUARTER HIGHLIGHTSNet income increased 76% to $26.7 million. On an adjusted basis1, net income increased 45% to $26.8 million. Diluted earnings per share (EPS) increased 62% to $0.34. On an adjusted basis1, diluted earnings per share increased 36% to $0.34. Adjusted EBITDA increased 33% to $47.9 million. Total...

Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash equivalents and marketable securities of $134.4 million as of September 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of tokenized assets, today announced financial results for the quarter ended September 30, 2025.  “We recently completed our successful initial public offering and are pleased to report a strong first quarter as a public company. The continued success of Figure’s marketplace approach to tokenized consumer loan origination drove significant growth in earnings, with Net Income increasing 227% year-over-year while also achieving an Adjusted EBITDA margin of 55%, underscoring the scalability of our blockchain-based model. Alongside margin expansion, we delivered solid performance across our key metrics, consumer loan marketplace volume, Adjusted Net Revenue,...

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC’s transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiation of registrational trials for both programs in 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,...

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange...